Table 2.
Efficacy of maintenance treatment with cetuximab.
| Events/number all population of study (n = 123) | Patients with type 2 diabetes mellitus (T2DM) taking metformin (n = 31) | Patients with type 2 diabetes mellitus (T2DM) NOT taking metformin (n = 26) | |
|---|---|---|---|
| Response rate: | |||
| Complete response (CR) | 2 (1.6%) | 1 (3.2%) | 1 (3.8%) |
| Partial response (PR) | 22 (17.9%) | 8 (25.8%) | 4 (15.4%) |
| Stable disease (SD) | 48 (39%) | 11 (35.5%) | 10 (38.5%) |
| Disease control (CR + PR + SD) | 72 (58.5%) | 20 (64.5%) | 15 (57.6%) |
| Progression disease (PD) | 50 (40.7%) | 11 (35.5%) | 11 (42.3%) |
| Not evaluable | 1 (0.8%) | – | – |
| PFS, months (95% CI) | 4.0 | 7 (95%CI 5–8) | 5 (95%CI 5–6) |
| OS, months (95% CI) | 8.0 | 11.0 (95%CI 10–12) | 8.5 (95%CI 7–10) |